$10.36
4.54% today
Nasdaq, Apr 02, 09:48 pm CET
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

uniQure N.V. Stock price

$9.91
-0.99 9.08% 1M
+5.29 114.50% 6M
-7.75 43.88% YTD
+4.70 90.21% 1Y
-9.54 49.05% 3Y
-35.72 78.28% 5Y
-13.63 57.89% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.69 6.51%
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

Key metrics

Market capitalization $535.90m
Enterprise Value $669.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 24.68
P/S ratio (TTM) P/S ratio 19.76
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 71.17%
Revenue (TTM) Revenue $27.12m
EBIT (operating result TTM) EBIT $-192.12m
Free Cash Flow (TTM) Free Cash Flow $-183.52m
Cash position $367.52m
EPS (TTM) EPS $-4.93
P/E forward negative
P/S forward 14.00
EV/Sales forward 17.48
Short interest 5.69%
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a uniQure N.V. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a uniQure N.V. forecast:

Buy
86%
Hold
14%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
27 27
71% 71%
100%
- Direct Costs 31 31
21% 21%
114%
-3.85 -3.85
60% 60%
-14%
- Selling and Administrative Expenses 33 33
34% 34%
123%
- Research and Development Expense 142 142
4% 4%
524%
-179 -179
14% 14%
-662%
- Depreciation and Amortization 13 13
6% 6%
47%
EBIT (Operating Income) EBIT -192 -192
13% 13%
-708%
Net Profit -240 -240
22% 22%
-883%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Neutral
GlobeNewsWire
about one month ago
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~
Positive
Seeking Alpha
about one month ago
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have ...
Positive
Seeking Alpha
about one month ago
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $2...
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 209
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today